Skip to main
  1. Stocks
  2. Incyte
  3. Forecast
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is viewed favorably because its core revenue engine remains robust, with Jakafi sales of $826.5 million in 3Q26 and underlying demand up about 12% year over year, while Opzelura delivered $254.9 million, up about 36% year over year and supported by stronger prescription demand and new patient starts. The broader ex-Jakafi portfolio also continues to scale, generating about $490 million and rising roughly 37% year over year, which helped management raise FY26 net sales guidance to $5.21 billion to $5.30 billion. Beyond the near-term commercial strength, the company has multiple pipeline catalysts across oncology and dermatology, and its strategic shift toward more attractive programs such as 1L ovarian maintenance and next-generation MPN assets supports longer-term growth despite the eventual Jakafi patent cliff.

Bears say

Incyte is facing a structurally difficult outlook because Jakafi remains the primary revenue source, yet its patent expiry in the 2028 timeframe creates a looming cliff that the current life-cycle strategy may not fully bridge. Its efforts to fragment the myelofibrosis market with combinations and CALR- or JAK2V617F-targeted approaches still carry a high bar, while competitors may have stronger activity across both Type 1 and non-Type 1 patients and could limit future share. Meanwhile, Opzelura may only generate $50-100M per year in milder HS, and the broader pipeline is still uncertain with regulatory risk and possible clinical setbacks in Phase I, II, and III programs.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Incyte (INCY) Analyst Forecast & Price Prediction

Get the latest Incyte (INCY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Incyte (INCY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Incyte (INCY) Analyst Forecast & Price Prediction

Get the latest Incyte (INCY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Incyte (INCY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INCY stock data and trends